[Myrin P in the combined treatment of tuberculosis]. / Mairin-P v kompleksnoi terapii tuberkuleza.

Experimental and clinical evaluation of the new antimycobacterial quadrocomposition Myrin P was performed. The composition consists of isoniazid, rifampicin, pyrazinamide and ethambutol in fixed doses. The results of the formulation application at 474 patients with primary pulmonary tuberculosis caused by drug-susceptible and drug-resistant mycobacteria are presented. High efficacy and good tolerability of the formulation was demonstrated.

[Tarivid in the combination therapy of patients with pulmonary tuberculosis]. / Tarivid v kompleksnoi terapii bol'nykh tuberkulezom legkikh.

The effectiveness of tarivid, a new drug having a broad spectrum of antimicrobial action and antituberculous effect, was studied. The drug was given to 29 patients with newly detected destructive pulmonary tuberculosis and bacillary excretion. Eight patients had microbacterial resistance to streptomycin, rifampicin and isoniazid, 12 had tolerance to them, in 9 patients tuberculosis was complicated by a nonspecific inflammatory process. The course of treatment ranged from 3 weeks to 3 months. The drug was well tolerated. Its effect was manifested by reduction of intoxication, resolution of the inflammatory and pericavitary pulmonary lesions and bacilli absence. Tarivid can be considered an efficacious drug in the multimodality therapy of tuberculosis patients.

[Pharmacokinetic bases for the drug-free prevention of drug-induced hepatitis in pulmonary tuberculosis patients]. / Farmakokineticheskie osnovy bezmedikamentoznoi profilaktiki lekarstvennykh gepatitov u bol'nykh tuberkulezom legkikh.

The causes and frequency of occurrence of toxic hepatitides determined by isoniazid and rifampicin, were analysed in 551 patients with primary tuberculosis detected by clinical pharmacological methods. The intravenous mode of drug administration was shown to be indicated for prevention of isoniazid hepatitides in patients with a fast type of acetylation. Doses and methods of therapy with isoniazid and streptomycin leading to their high concentrations in the patients' body should be avoided to prevent liver affection with rifampicin. Since rifampicin hepatitides develop in persons with a slow type of acetylation, rifampicin and isoniazid with streptomycin should be injected with a 6-hour interval to prevent them.

[Use of agar diffusion method for separate determination of concentration of streptomycin and rifampicin in the blood in the presence of isoniazid]. / Metod diffuzii v agar dlia razdel'nogo opredeleniia kontsentratsii streptomitsina i rifampitsina pri ikh sovmestnom prisutstvii s izoniazidom v syvorotke krovi.

Conditions for determination of streptomycin and rifampicin in the blood serum on their combined use, as well as in the presence of isoniazid are described. For determination of the blood levels of streptomycin administered in combination with rifampicin it is recommended tat a variant of Bac. mycoides 537 resistant to rifampicin be used. When the rifampicin levels are determined in undiluted serum, the value obtained should be multiplied by 1.4. When a 2-fold dilution of the serum is used, the value is multiplied by 1.15. This provides an indicator maximally close to the real content of the antibiotic in the blood serum.